News | August 02, 2011

Study Shows Cigarette Smoking Increases Risk of Developing Atrial Fibrillation


August 2, 2011 — Results from a large, United States-based cohort study show that current smokers double their risk of developing atrial fibrillation (AF) compared to people who have never smoked, after more than 13 years of follow-up. The study, published in the August edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), indicates a trend towards significantly lower risk of developing AF for those who quit smoking cigarettes versus those who continue to smoke.

According to the HRS, AF is a very common heart rhythm disorder with more than 2 million people in the United States diagnosed and about 160,000 new cases identified each year. While several risk factors have been identified, including obesity, hypertension and diabetes, the association between smoking and AF is less clear.

Between 1987 and 1989, the Atherosclerosis Risk in Communities (ARIC) study enrolled a population-based cohort of over 15,000 black and white participants aged 45-64 years. All participants were questioned at baseline about the number of cigarettes smoked per day, smoking status (current, former or never) and age at smoking initiation or cessation.

Study analysis conducted by Alanna Chamberlain, Ph.D., and co-authors reports 876 incident AF events during an average 13-year follow-up period. The risk of AF was found to be 1.32 times greater among former smokers and twofold higher in current smokers than in nonsmokers. In addition, compared to nonsmokers, former heavy smokers had an 89 percent increased risk of developing AF, while current heavy smokers had a 131 percent increased risk, indicating that quitting smoking lowers the risk of developing AF.  Specifically, there was a 12 percent lower risk of AF among individuals who quit smoking versus individuals who continued smoking.

“AF is a serious health issue that decreases quality of life and significantly increases the risk of stroke,” stated co-author Alanna M. Chamberlain, Ph.D, MPH, department of health sciences research at the Mayo Clinic in Rochester, Minn. “It is my hope that our study findings will shed more light on the impact that smoking has on cardiovascular diseases, and help individuals realize they can play a role in preventing the development of atrial fibrillation.”

These results support previous findings that smoking increases the risk of AF development. The findings also show that associations between smoking and AF do not differ between blacks and whites, despite overall incident rates being lower in blacks. Furthermore, this is the first study to document differences in AF development between participants who remained smokers throughout the study follow-up and those who stopped smoking. Future studies may choose to focus on the role of smoking cessation in the prevention of AF development.

For more information: www.heartrhythmjournal.com


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now